Literature DB >> 23824488

Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology.

Beatriz G Perez-Nievas1, Thor D Stein, Hwan-Ching Tai, Oriol Dols-Icardo, Thomas C Scotton, Isabel Barroeta-Espar, Leticia Fernandez-Carballo, Estibaliz Lopez de Munain, Jesus Perez, Marta Marquie, Alberto Serrano-Pozo, Mathew P Frosch, Val Lowe, Joseph E Parisi, Ronald C Petersen, Milos D Ikonomovic, Oscar L López, William Klunk, Bradley T Hyman, Teresa Gómez-Isla.   

Abstract

Clinico-pathological correlation studies and positron emission tomography amyloid imaging studies have shown that some individuals can tolerate substantial amounts of Alzheimer's pathology in their brains without experiencing dementia. Few details are known about the neuropathological phenotype of these unique cases that might prove relevant to understanding human resilience to Alzheimer's pathology. We conducted detailed quantitative histopathological and biochemical assessments on brains from non-demented individuals before death whose brains were free of substantial Alzheimer's pathology, non-demented individuals before death but whose post-mortem examination demonstrated significant amounts of Alzheimer's changes ('mismatches'), and demented Alzheimer's cases. Quantification of amyloid-β plaque burden, stereologically-based counts of neurofibrillary tangles, neurons and reactive glia, and morphological analyses of axons were performed in the multimodal association cortex lining the superior temporal sulcus. Levels of synaptic integrity markers, and soluble monomeric and multimeric amyloid-β and tau species were measured. Our results indicate that some individuals can accumulate equivalent loads of amyloid-β plaques and tangles to those found in demented Alzheimer's cases without experiencing dementia. Analyses revealed four main phenotypic differences among these two groups: (i) mismatches had striking preservation of neuron numbers, synaptic markers and axonal geometry compared to demented cases; (ii) demented cases had significantly higher burdens of fibrillar thioflavin-S-positive plaques and of oligomeric amyloid-β deposits reactive to conformer-specific antibody NAB61 than mismatches; (iii) strong and selective accumulation of hyperphosphorylated soluble tau multimers into the synaptic compartment was noted in demented cases compared with controls but not in mismatches; and (iv) the robust glial activation accompanying amyloid-β and tau pathologies in demented cases was remarkably reduced in mismatches. Further biochemical measurements of soluble amyloid-β species-monomers, dimers and higher molecular weight oligomers-in total brain homogenates and synaptoneurosomal preparations failed to demonstrate significant differences between mismatches and demented cases. Together, these data suggest that amyloid-β plaques and tangles do not inevitably result in neural system derangement and dementia in all individuals. We identified distinct phenotypic characteristics in the profile of brain fibrillar and soluble amyloid-β and tau accrual and in the glial response that discriminated demented and non-demented individuals with high loads of Alzheimer's pathology. Amyloid-β deposition in the form of fibrillar plaques and intimately related oligomeric amyloid-β assemblies, hyperphosphorylated soluble tau species localized in synapses, and glial activation emerged in this series as likely mediators of neurotoxicity and altered cognition, providing further insight into factors and pathways potentially involved in human susceptibility or resilience to Alzheimer's pathological changes.

Entities:  

Keywords:  Alzheimers disease; amyloid pathology; astrocytes; microglia; resilience; tau pathology

Mesh:

Substances:

Year:  2013        PMID: 23824488      PMCID: PMC3722351          DOI: 10.1093/brain/awt171

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  62 in total

1.  Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease.

Authors:  B DaRocha-Souto; M Coma; B G Pérez-Nievas; T C Scotton; M Siao; P Sánchez-Ferrer; T Hashimoto; Z Fan; E Hudry; I Barroeta; L Serenó; M Rodríguez; M B Sánchez; B T Hyman; T Gómez-Isla
Journal:  Neurobiol Dis       Date:  2011-09-13       Impact factor: 5.996

2.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

3.  Relationship between regional atrophy rates and cognitive decline in mild cognitive impairment.

Authors:  Carrie R McDonald; Lusineh Gharapetian; Linda K McEvoy; Christine Fennema-Notestine; Donald J Hagler; Dominic Holland; Anders M Dale
Journal:  Neurobiol Aging       Date:  2010-05-14       Impact factor: 4.673

Review 4.  Anti-inflammatory drugs in the fight against Alzheimer's disease.

Authors:  P L McGeer; E G McGeer
Journal:  Ann N Y Acad Sci       Date:  1996-01-17       Impact factor: 5.691

5.  Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β.

Authors:  Robert M Koffie; Tadafumi Hashimoto; Hwan-Ching Tai; Kevin R Kay; Alberto Serrano-Pozo; Daniel Joyner; Steven Hou; Katherine J Kopeikina; Matthew P Frosch; Virginia M Lee; David M Holtzman; Bradley T Hyman; Tara L Spires-Jones
Journal:  Brain       Date:  2012-05-26       Impact factor: 13.501

6.  Variant of TREM2 associated with the risk of Alzheimer's disease.

Authors:  Thorlakur Jonsson; Hreinn Stefansson; Stacy Steinberg; Ingileif Jonsdottir; Palmi V Jonsson; Jon Snaedal; Sigurbjorn Bjornsson; Johanna Huttenlocher; Allan I Levey; James J Lah; Dan Rujescu; Harald Hampel; Ina Giegling; Ole A Andreassen; Knut Engedal; Ingun Ulstein; Srdjan Djurovic; Carla Ibrahim-Verbaas; Albert Hofman; M Arfan Ikram; Cornelia M van Duijn; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  N Engl J Med       Date:  2012-11-14       Impact factor: 91.245

7.  Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease.

Authors:  P V Arriagada; K Marzloff; B T Hyman
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

8.  The neuropathology of older persons with and without dementia from community versus clinic cohorts.

Authors:  Julie A Schneider; Neelum T Aggarwal; Lisa Barnes; Patricia Boyle; David A Bennett
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 9.  Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies.

Authors:  Stephen W Scheff; Douglas A Price
Journal:  Neurobiol Aging       Date:  2003-12       Impact factor: 4.673

10.  Trans-synaptic spread of tau pathology in vivo.

Authors:  Li Liu; Valerie Drouet; Jessica W Wu; Menno P Witter; Scott A Small; Catherine Clelland; Karen Duff
Journal:  PLoS One       Date:  2012-02-01       Impact factor: 3.240

View more
  145 in total

1.  Topological analyses in APP/PS1 mice reveal that astrocytes do not migrate to amyloid-β plaques.

Authors:  Elena Galea; Will Morrison; Eloise Hudry; Michal Arbel-Ornath; Brian J Bacskai; Teresa Gómez-Isla; H Eugene Stanley; Bradley T Hyman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-07       Impact factor: 11.205

2.  TDP-43 is a key player in the clinical features associated with Alzheimer's disease.

Authors:  Keith A Josephs; Jennifer L Whitwell; Stephen D Weigand; Melissa E Murray; Nirubol Tosakulwong; Amanda M Liesinger; Leonard Petrucelli; Matthew L Senjem; David S Knopman; Bradley F Boeve; Robert J Ivnik; Glenn E Smith; Clifford R Jack; Joseph E Parisi; Ronald C Petersen; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2014-03-23       Impact factor: 17.088

3.  [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging.

Authors:  Marta Marquié; Michael Siao Tick Chong; Alejandro Antón-Fernández; Eline E Verwer; Nil Sáez-Calveras; Avery C Meltzer; Prianca Ramanan; Ana C Amaral; Jose Gonzalez; Marc D Normandin; Matthew P Frosch; Teresa Gómez-Isla
Journal:  Acta Neuropathol       Date:  2017-06-13       Impact factor: 17.088

Review 4.  The intersection of amyloid beta and tau at synapses in Alzheimer's disease.

Authors:  Tara L Spires-Jones; Bradley T Hyman
Journal:  Neuron       Date:  2014-05-21       Impact factor: 17.173

5.  Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia.

Authors:  Andrew P Merluzzi; Cynthia M Carlsson; Sterling C Johnson; Suzanne E Schindler; Sanjay Asthana; Kaj Blennow; Henrik Zetterberg; Barbara B Bendlin
Journal:  Neurology       Date:  2018-06-29       Impact factor: 9.910

6.  The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease.

Authors:  Mari Paz Serrano; Raquel Herrero-Labrador; Hunter S Futch; Julia Serrano; Alejandro Romero; Ana Patricia Fernandez; Abdelouahid Samadi; Mercedes Unzeta; Jose Marco-Contelles; Ricardo Martínez-Murillo
Journal:  J Psychiatry Neurosci       Date:  2017-01       Impact factor: 6.186

Review 7.  Future Directions in Imaging Neurodegeneration.

Authors:  Joseph C Masdeu
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

8.  Amyloid burden accelerates white matter degradation in cognitively normal elderly individuals.

Authors:  Ashwati Vipin; Kwun Kei Ng; Fang Ji; Hee Youn Shim; Joseph K W Lim; Ofer Pasternak; Juan Helen Zhou
Journal:  Hum Brain Mapp       Date:  2019-01-03       Impact factor: 5.038

Review 9.  The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases.

Authors:  Filippo Baldacci; Sonia Mazzucchi; Alessandra Della Vecchia; Linda Giampietri; Nicola Giannini; Maya Koronyo-Hamaoui; Roberto Ceravolo; Gabriele Siciliano; Ubaldo Bonuccelli; Fanny M Elahi; Andrea Vergallo; Simone Lista; Filippo Sean Giorgi; Harald Hampel
Journal:  Expert Rev Mol Diagn       Date:  2020-02-27       Impact factor: 5.225

Review 10.  Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain?

Authors:  Guillermo Moya-Alvarado; Noga Gershoni-Emek; Eran Perlson; Francisca C Bronfman
Journal:  Mol Cell Proteomics       Date:  2015-12-11       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.